Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Research & Development (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Research & Development for 4 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 62.82% to $25.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.4 million through Dec 2025, up 30.91% year-over-year, with the annual reading at $86.4 million for FY2025, 30.91% up from the prior year.
  • Research & Development hit $25.0 million in Q4 2025 for Taysha Gene Therapies, down from $25.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $25.7 million in Q3 2025 to a low of -$40.6 million in Q4 2023.
  • Historically, Research & Development has averaged $13.1 million across 4 years, with a median of $15.4 million in 2024.
  • Biggest YoY gain for Research & Development was 1151.4% in 2023; the steepest drop was 419.48% in 2023.
  • Year by year, Research & Development stood at $12.7 million in 2022, then tumbled by 419.48% to -$40.6 million in 2023, then soared by 137.75% to $15.3 million in 2024, then skyrocketed by 62.82% to $25.0 million in 2025.
  • Business Quant data shows Research & Development for TSHA at $25.0 million in Q4 2025, $25.7 million in Q3 2025, and $20.1 million in Q2 2025.